High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group.

Symptomatic brain metastases are found in about 40% of patients with small cell lung cancer. Cranial irradiation is the first line treatment for this form of metastatic disease. Frequently brain metastases recur after this treatment or develop after prophylactic cranial irradiation. For these patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Postmus, P. E., Haaxma-Reiche, H., Sleijfer, D. T., Kirkpatrick, A., McVie, J. G., Kleisbauer, J. P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246989/
https://www.ncbi.nlm.nih.gov/pubmed/2539174
Descripción
Sumario:Symptomatic brain metastases are found in about 40% of patients with small cell lung cancer. Cranial irradiation is the first line treatment for this form of metastatic disease. Frequently brain metastases recur after this treatment or develop after prophylactic cranial irradiation. For these patients no effective antitumour therapy is available. In this study the efficacy of high dose etoposide 1.5 g m-2 was evaluated. In 10 (43%) out of 23 evaluable patients a response was seen. Toxicity was severe with five aplasia-related deaths. For palliative purposes this regimen is too toxic in heavily pretreated patients.

Ejemplares similares